STOCK TITAN

BioNexus Gene Lab (BGLC) SEC Filings, Jun-Jul 2025

BGLC NASDAQ

BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.

The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.

Rhea-AI Summary

BioNexus Gene Lab Corp. (Nasdaq: BGLC) filed an 8-K to disclose a Regulation FD communication. On 30 July 2025 the company signed a non-binding term sheet with Singapore-based Fidelion Diagnostics Pte Ltd. The parties are negotiating a cross-equity strategic alliance and have granted BGLC exclusive commercialization rights in Southeast Asia to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) testing platform, a precision-oncology technology aimed at detecting trace cancer cells post-treatment.

The agreement is still preliminary; no financial terms, timelines or definitive contracts were announced. The company framed the deal as a potential “DeepSeek Moment” for oncology diagnostics in the region. No guidance, revenue impact or financing details accompanied the disclosure, and the item is being furnished, not filed, so it carries no immediate accounting effect.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.99%
Tags
current report
-
Rhea-AI Summary
BioNexus Gene Lab Corp (NASDAQ: BGLC) announced the appointment of Ms. Chong Set Fui (Angeline) as Chief Financial Officer and Principal Financial Officer, effective June 17, 2025. Ms. Chong, 62, brings over 25 years of senior financial leadership experience, including her previous role as CFO of Avillion Berhad (2013-2024). She holds ACCA and MIA certifications. The appointment includes dual responsibilities as CFO of MRNA Scientific Sdn. Bhd., a wholly-owned subsidiary. Her compensation package consists of RM15,000 monthly (approx. USD $3,500) plus benefits. Mr. Su-Leng Tan Lee steps down from his interim CFO position. The appointment was vetted by the Nomination and Corporate Governance Committee and Compensation Committee, with an indemnification agreement governed by Wyoming law. BGLC is an emerging growth company listed on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
current report

FAQ

How many BioNexus Gene Lab (BGLC) SEC filings are available on StockTitan?

StockTitan tracks 32 SEC filings for BioNexus Gene Lab (BGLC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BioNexus Gene Lab (BGLC)?

The most recent SEC filing for BioNexus Gene Lab (BGLC) was filed on November 16, 2026.